60 Degrees Pharmaceuticals Stock Fell Ahead of Trial Data

Shareholders await interim clinical results on a potential new use for an existing FDA-approved malaria drug.

Updated on Oct. 6, 2026 in Healthcare

Bold vector editorial illustration of a laboratory glass vial containing amber liquid, representing medical clinical research. — Shares of 60 Degrees Pharmaceuticals declined 6.22% on Tuesday as investors awaited interim clinical trial results for the drug tafenoquine. AI Illustration. Upload story photo >

Live Poll

Is now a good time for you to invest in small-cap pharmaceutical stocks?

Shares of 60 Degrees Pharmaceuticals dropped 6.22% in Tuesday pre-market trading to $1.35. The movement occurred ahead of a company-scheduled disclosure regarding interim clinical trial results for tafenoquine.

Why it matters

The company is seeking to expand the utility of its FDA-approved malaria drug to include babesiosis, a condition that currently lacks any approved treatments or vaccines. Investors are tracking the clinical data for signs of potential market viability for this specialized therapeutic.

60 Degrees Pharmaceuticals currently carries a market capitalization of $5.06 million across 3.52 million shares outstanding. The stock's Relative Strength Index stands at 70.62, while the company prepares to discuss study findings during an investor webinar.

The players

60 Degrees Pharmaceuticals

A Washington-based developer focused on clinical-stage pharmaceutical solutions and the repurposing of existing drug therapies.

The details

60 Degrees Pharmaceuticals is testing tafenoquine, an existing malaria treatment, for efficacy against babesiosis. Management scheduled an investor webinar for 11 a.m. ET Tuesday to review interim findings from the clinical trial. The firm is currently evaluating whether this repurposing strategy can address the complete lack of FDA-approved alternatives for the disease.

Monday: The stock closed at $1.44 per share.
Tuesday: Pre-market shares traded at $1.35 before the interim results disclosure and investor webinar.

Market Landscape

The firm's reliance on tafenoquine reflects a common industry strategy of repurposing existing FDA-approved assets to address orphan conditions. This trial marks a critical attempt to extend the drug's utility into a space currently lacking any approved treatment options.

Operators should monitor whether the upcoming clinical disclosure establishes a clear commercial path for the drug, which would impact the competitive landscape for malaria and tick-borne illness therapeutics. The company's market cap of $5.06 million suggests high volatility for investors and partners to factor into risk models.

The takeaway

The firm's pivot toward babesiosis represents a significant test for its primary asset's revenue potential. Observers should track the outcome of the investor webinar to gauge whether the clinical data supports an expanded regulatory filing.